What is the outpatient pharmacological management of proctitis?

Outpatient Pharmacological Management of Proctitis

For mild to moderate ulcerative proctitis, start with mesalamine (5-ASA) 1 gram suppository once daily at bedtime as first-line therapy. 1, 2

First-Line Treatment Algorithm

Initial Therapy

• Mesalamine 1g suppository once daily is the preferred formulation over enemas or foam because suppositories deliver drug more effectively to the rectum and are better tolerated 1
• Suppositories are superior to oral 5-ASA monotherapy for disease confined to the rectum 1, 2
• Topical mesalamine is more effective than topical corticosteroids (pooled OR 1.65 for symptomatic remission) 3
• Assess response at 4-8 weeks 3

If Incomplete Response After 4-8 Weeks

Add oral 5-ASA 2-3 grams daily to the suppository regimen 2

• Combination topical plus oral therapy is more effective than either alone 1
• Continue for another 4-8 weeks before escalating

If Still Inadequate Response

Switch to or add corticosteroid suppository (e.g., prednisolone 5mg in morning) while continuing 5-ASA suppository at night 2

• Optimize oral 5-ASA to 4-4.8 grams daily 2
• Budesonide 4mg suppository is equivalent to 5-ASA 1g but not superior 2

Refractory Disease

If no response to combined topical and oral therapy:

• Oral prednisolone 40mg once daily, taper over 6-8 weeks 2
• For steroid-dependent or refractory cases: consider immunomodulators (thiopurines) or biologics (anti-TNF, vedolizumab) 1

Maintenance Therapy

Continue the same therapy that induced remission 3

• For patients who respond to 5-ASA suppositories: continue 1g suppository daily 2
• Can reduce frequency to every 2nd or 3rd night to improve adherence without substantially reducing efficacy 4
• Many patients with infrequent flares prefer on-demand treatment rather than continuous maintenance, which is acceptable since colorectal cancer risk in proctitis equals general population 2

Critical Pitfalls to Avoid

Before escalating therapy, always:

1. Verify adherence - poor compliance is the most common cause of treatment failure 1, 2
2. Confirm diagnosis - exclude infection (including sexually transmitted), Crohn's disease, solitary rectal ulcer, chemical colitis, rectal prolapse 2
3. Check for proximal constipation - common in distal colitis and impairs drug delivery; treat with laxatives if present 1, 2
4. Reassess with sigmoidoscopy - rule out proximal disease extension 2

Key Evidence Points

The recommendation for topical 5-ASA is supported by high-quality evidence showing dramatic superiority over placebo (OR 8.3 for symptomatic remission, OR 5.3 for endoscopic remission) 1. The 2019 British Society of Gastroenterology guidelines 2 and 2017 ECCO guidelines 1 provide the most recent consensus, both giving strong recommendations with high-quality evidence for 1g mesalamine suppositories as first-line therapy.

There is no dose-response benefit above 1 gram daily for topical therapy 1, so higher doses are unnecessary and waste resources.

Approximately 30% of proctitis cases become refractory to conventional therapy 5, requiring systematic escalation through the algorithm above rather than premature advancement to biologics.